Clinical Trials | A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects with Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

The University of Virginia is conducting a clinical research study for adults age 18 and older with platinum-resistant, high-grade ovarian, primary peritoneal, or fallopian tube cancer. The purpose of this study is to evaluate an investigational medication called raludotatug deruxtecan (R-DXd). R-DXd is a type of targeted therapy known as an antibody-drug conjugate, which is designed to deliver chemotherapy directly to cancer cells and not healthy cells. Participants in this study will be assigned by chance (like flipping a coin) to receive either: • R-DXd, given by intravenous (IV) infusion in your arm once every 3 weeks, or • Standard-of-care chemotherapy, which may include paclitaxel, topotecan, or pegylated liposomal doxorubicin (PLD). The specific standard-of-care treatment and dosing schedule will be determined by the study doctor. Treatment will continue until the study doctor or study sponsor determines that treatment should stop, or until you choose to withdraw from the study. Study-related tests and procedures that go beyond standard medical care will be provided at no cost to you or your insurance. Additional information can be found here: https://clinicaltrials.gov/study/NCT06161025